9-Bromo-4,5-dihydro-[1]benzoxepino[5,4-d]thiazole-2-carboxamide → (+/-)-9-((3-Hydroxy-1-methyl-2-oxopiperidin-3-yl)ethynyl)-4,5-dihydrobenzo[2,3]oxepino[4,5-d]thiazole-2-carboxamide
반응식
Br[C:2]1[CH:18]=[CH:17][C:5]2[O:6][CH2:7][CH2:8][C:9]3[S:13][C:12]([C:14]([NH2:16])=[O:15])=[N:11][C:10]=3[C:4]=2[CH:3]=1.[C:19]([C:21]1([OH:29])[CH2:26][CH2:25][CH2:24][N:23]([CH3:27])[C:22]1=[O:28])#[CH:20]>>[OH:29][C:21]1([C:19]#[C:20][C:2]2[CH:18]=[CH:17][C:5]3[O:6][CH2:7][CH2:8][C:9]4[S:13][C:12]([C:14]([NH2:16])=[O:15])=[N:11][C:10]=4[C:4]=3[CH:3]=2)[CH2:26][CH2:25][CH2:24][N:23]([CH3:27])[C:22]1=[O:28]참가 물질
3
실험 절차
Similar to as described in General Procedure G, 9-bromo-4,5-dihydrobenzo[2,3]oxepino[4,5-d]thiazole-2-carboxamide was reacted with 3-ethynyl-3-hydroxy-1-methylpiperidin-2-one to give the titled compound as a white solid (10 mg, 8%).
출처 및 근거
- ORD 기록
- ord-9dcaa9f2350245a1afebce870b715146
- 출처 데이터셋
- uspto-grants-2015_05
- 특허 번호
- US09034866B2
반응 노트
불러오는 중…